Taft’s Intellectual Property Litigation practice and two partners are recognized in the seventh edition of "IAM Patent 1000 – The World’s Leading Patent Professionals," published by Intellectual Asset Management (IAM) magazine. In the guide, Taft received Bronze band honors “thanks to a gilt-edged pharmaceutical and life sciences litigation practice.” Pharmaceutical and Life Sciences Practice chair Stephen Auten is recognized as “one of the most knowledgeable ANDA litigation experts” who “has the right answer for any question.” Richard Ruzich is noted as “another top lawyer” and a multi-talented litigator and IP asset manager.
IAM conducts intensive research and interviews to identify the top patent professionals and practices. Individuals qualify for the IAM Patent 1000 once they receive sufficient positive feedback from peers and clients with knowledge of their practice and the market within which they operate. Only those individuals identified by market sources for their exceptional skill sets and profound insights into patent matters are featured in the guide.
Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 8,500 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in ANDA litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.